Skip to content
Inciteful Med

Recognizing and Diagnosing FNAIT in Your Newborn

Last updated:

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is typically diagnosed after birth when a newborn presents with low platelets, bruising, or petechiae. Diagnosis is confirmed through maternal antibody screening and genetic testing (HPA genotyping) of the parents.

Key Takeaways

  • • FNAIT is rarely caught during pregnancy due to a lack of universal screening, meaning the condition is usually discovered after the first affected baby is born.
  • • Common visible symptoms in newborns include petechiae, bruising, and mucosal bleeding caused by dangerously low platelet counts.
  • • The most severe complication of FNAIT is intracranial hemorrhage (ICH), which can occur in utero and requires a cranial ultrasound to detect.
  • • Diagnosis is confirmed through specialized blood tests, including maternal antibody screening and HPA genotyping.
  • • Testing the father's genetics is crucial to determine if future pregnancies will have a 50% or 100% risk of developing FNAIT.

When a baby is born with FNAIT, the diagnosis often feels like a race against time. Because there is currently no universal screening for this condition during pregnancy, most parents only learn about it after their baby shows visible signs of low platelets [1][2].

Visible Symptoms in the Newborn

The most common signs of FNAIT are visible on the skin. These symptoms appear because the baby’s platelet count is too low to prevent small leaks in the blood vessels [3].

  • Petechiae: These are tiny, circular, red or purple spots that look like a rash [4]. They are actually tiny pinprick bleeds under the skin and are often the first sign a medical team notices [3][5].
  • Bruising and Hematomas: A baby may have larger bruises (ecchymosis) or raised lumps of blood (hematomas), especially on areas like the abdomen or where they were handled during delivery, such as the scalp or heels [3][4].
  • Mucosal Bleeding: In some cases, bleeding may occur in the gums, nose, or even show up in the baby’s urine or stool [6].

The Most Critical Complication: ICH

The most serious risk associated with FNAIT is Intracranial Hemorrhage (ICH), which is bleeding inside or around the brain [7].

  • Incidence: In the general population, FNAIT-related ICH occurs in approximately 1 in 10,000 live births [8]. However, for babies diagnosed with severe FNAIT, the risk of ICH is significantly higher if left untreated, occurring in up to 10-20% of severe cases [8][6].
  • Timing: While ICH can happen after birth, many cases actually occur in utero (while the baby is still in the womb) before the mother even goes into labor [8][6].
  • Monitoring: If FNAIT is suspected, doctors will often perform a “cranial ultrasound”—a painless imaging test—to check for any signs of bleeding in the baby’s brain [4][9].

How Doctors Confirm the Diagnosis

Confirming FNAIT requires specialized laboratory testing that goes beyond a standard blood count.

  1. Serology (Antibody Screening): Doctors test the mother’s blood to see if she has antibodies that attack platelets. Common tests include MAIPA (Monoclonal Antibody-Specific Immobilization of Platelet Antigens) or Luminex assays, which are highly sensitive ways to “see” the specific antibodies in her system [10][11].
  2. Genotyping: This is a genetic test that looks at the DNA of the mother, the father, and sometimes the baby [10]. Genotyping determines which specific Human Platelet Antigens (HPA) each person has [12].
    • If the father is homozygous for the antigen (meaning he has two copies of the “mismatched” gene), every future child he has with that mother will also be at risk [9][12].
    • If he is heterozygous (meaning he has one copy), there is a 50% chance each future child will inherit the targeted antigen and be at risk for FNAIT [9].

Why Wasn’t This Found Sooner?

It is natural to wonder why this wasn’t caught during routine prenatal care. Currently, universal antenatal screening (testing every pregnant woman for HPA incompatibility) is not standard practice [9][13]. This is because the condition is rare, the tests are specialized, and there is ongoing debate among experts about the cost-effectiveness and potential for over-treatment in cases that might have been mild [14][15]. Consequently, the first “affected” baby in a family is often the one who leads to the diagnosis [7][16].

Frequently Asked Questions

What are the first signs of FNAIT in a newborn?
The most common early signs are visible on the skin, including tiny red or purple spots called petechiae, larger bruises, or raised lumps of blood (hematomas). These occur because the baby's platelet count is too low to prevent small leaks in blood vessels.
Why wasn't FNAIT caught during my pregnancy?
There is currently no universal prenatal screening for FNAIT because the condition is rare and the required tests are highly specialized. As a result, parents usually only learn about it when their newborn shows signs of low platelets after birth.
What is the risk of intracranial hemorrhage (ICH) with FNAIT?
Intracranial hemorrhage, or bleeding inside the brain, is the most serious complication of FNAIT. It occurs in up to 10-20% of severe, untreated cases and can often happen while the baby is still in the womb. Doctors use cranial ultrasounds to check for this complication.
How do doctors confirm a FNAIT diagnosis?
Doctors confirm FNAIT using specialized lab tests. This includes serology to check the mother's blood for platelet-attacking antibodies, and genotyping to examine the DNA of the parents and baby.
What does it mean if the father is homozygous for an HPA antigen?
If genetic testing shows the father is homozygous for the mismatched antigen, it means he carries two copies of that gene. Consequently, every future child he has with the mother will inherit the antigen and be at risk for FNAIT.

Questions for Your Doctor

  • • Has a cranial ultrasound or MRI been performed to rule out intracranial hemorrhage?
  • • What laboratory method (such as MAIPA or Luminex) was used to confirm the presence of maternal antibodies?
  • • Is the father being tested for HPA genotyping, and if so, is he 'homozygous' or 'heterozygous' for the antigen?
  • • Based on the baby's current platelet count, how frequently will they need blood tests over the next week?
  • • Are there any other types of internal bleeding, such as gastrointestinal or renal, that we should be concerned about?

Questions for You

  • • Did you notice any small red dots (petechiae) or bruising immediately at birth, or did they appear later?
  • • In your previous pregnancies (if any), were there any unexplained issues with the baby's health or your own blood counts?
  • • How are you managing the stress of these tests and results while also caring for a newborn?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Management of high-risk pregnancies in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group].

    Bertrand G,

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 2021; (28(4)):370-374 doi:10.1016/j.tracli.2021.08.349.

    PMID: 34464715
  2. 2

    Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia.

    de Vos TW, Winkelhorst D, de Haas M, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102704 doi:10.1016/j.transci.2019.102704.

    PMID: 31974030
  3. 3

    Subamniotic Hemorrhage, a Possible New Presentation of Fetal and Neonatal Alloimmune Thrombocytopenia.

    Giesbers S, Bos M, Bulten J, et al.

    Fetal diagnosis and therapy 2022; (49(1-2)):60-64 doi:10.1159/000521866.

    PMID: 35021176
  4. 4

    A Neonate with FNAIT Supported by Placental Chronic Histiocytic Intervillositis and Confounded by Maternal Preeclampsia: A Case Report.

    White H, Sybenga A

    AJP reports 2025; (15(3)):e163-e165 doi:10.1055/a-2703-4068.

    PMID: 41041599
  5. 5

    Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia.

    Curtis BR

    British journal of haematology 2015; (171(5)):671-82 doi:10.1111/bjh.13639.

    PMID: 26344048
  6. 6

    Severe bleeding complications other than intracranial hemorrhage in neonatal alloimmune thrombocytopenia: a case series and review of the literature.

    Winkelhorst D, Kamphuis MM, de Kloet LC, et al.

    Transfusion 2016; (56(5)):1230-5 doi:10.1111/trf.13550.

    PMID: 26996515
  7. 7

    Management of neonatal thrombocytopenia in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group.

    Bertrand G, Blouin L, Boehlen F, et al.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2019; (26(3)):191-197 doi:10.1016/j.arcped.2019.02.006.

    PMID: 30827773
  8. 8

    Clinical management in FNAIT - navigating a complicated landscape.

    Tiller H, Ahlen MT

    Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102681 doi:10.1016/j.bpobgyn.2025.102681.

    PMID: 41167021
  9. 9

    Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.

    Lieberman L, Greinacher A, Murphy MF, et al.

    British journal of haematology 2019; (185(3)):549-562 doi:10.1111/bjh.15813.

    PMID: 30828796
  10. 10

    Severe neonatal thrombocytopenia due to anti-HPA-4b alloantibodies: Third report described in a Caucasian mother.

    Petermann R, Bianchi F, Saib L, et al.

    Transfusion 2024; (64(6)):1167-1170 doi:10.1111/trf.17863.

    PMID: 38693097
  11. 11

    Sensitive detection of platelet-specific antibodies with a modified MAIPA using biotinylated antibodies and streptavidin-coated beads.

    Mörtberg A, Meinke S, Berg P, et al.

    Journal of immunological methods 2016; (434()):9-15.

    PMID: 27059653
  12. 12

    A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility.

    Ouzegdouh Mammasse Y, Chenet C, Drubay D, et al.

    British journal of haematology 2020; (190(5)):787-798 doi:10.1111/bjh.16593.

    PMID: 32266719
  13. 13

    Current perspectives on fetal and neonatal alloimmune thrombocytopenia - increasing clinical concerns and new treatment opportunities.

    Tiller H, Husebekk A, Ahlen MT, et al.

    International journal of women's health 2017; (9()):223-234 doi:10.2147/IJWH.S90753.

    PMID: 28458583
  14. 14

    Pregnant Women at Low Risk of Having a Child with Fetal and Neonatal Alloimmune Thrombocytopenia Do Not Require Treatment with Intravenous Immunoglobulin.

    Kjeldsen-Kragh J, Bein G, Tiller H

    Journal of clinical medicine 2023; (12(17)) doi:10.3390/jcm12175492.

    PMID: 37685558
  15. 15

    New developments in fetal and neonatal alloimmune thrombocytopenia.

    Bussel JB, Vander Haar EL, Berkowitz RL

    American journal of obstetrics and gynecology 2021; (225(2)):120-127 doi:10.1016/j.ajog.2021.04.211.

    PMID: 33839095
  16. 16

    From concept to practice: Screening for fetal and neonatal alloimmune thrombocytopenia (FNAIT).

    Pothof R, de Vos TW, Lopriore E, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102683 doi:10.1016/j.bpobgyn.2025.102683.

    PMID: 41161115

This page provides educational information about FNAIT symptoms and diagnosis in newborns. It is not a substitute for professional medical advice, diagnosis, or treatment by your baby's healthcare team.

Stay up to date

Get notified when new research about Fetal and neonatal alloimmune thrombocytopenia is published.

No spam. Unsubscribe anytime.